ReviewMolecules (Basel, Switzerland)2017
From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods.
Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 117 citations in OpenAlex.
- Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy.Clinics in perinatology · 2026Review
- Enhanced heparosan biosynthesis in Corynebacterium glutamicum by systematic metabolic engineering and translation-level fine-tuning.Bioresources and bioprocessing · 2026Article
- Should we focus on sustainable thromboprophylaxis and avoid overuse of low-molecular-weight heparins?Research and practice in thrombosis and haemostasis · 2026Article
- Advances in Transdermal Drug Delivery Systems for Antithrombotic Therapy: A Systematic Review.ACS pharmacology & translational science · 2025Review
- The Discovery, Characterization, and Quantification of Bioactive Peptides Contained in Palbio Porcine Intestinal Mucosa Hydrolysate Products.International journal of molecular sciences · 2025Article
- Eight Ways General Internists Can Practice High-Value, Low-Carbon Care: The Canadian Society of Internal Medicine's Climate Conscious Choosing Wisely Canada Recommendations.Journal of general internal medicine · 2025Article
- Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications.Discover oncology · 2025Review
- Article
- Glycosaminoglycan microarrays for studying glycosaminoglycan-protein systems.Carbohydrate polymers · 2024Review
- Synthesis of bioengineered heparin chemically and biologically similar to porcine-derived products and convertible to low MW heparin.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Green Nephrology: Citrate, the Green Alternative to Heparin in Hemodialysis.Kidney international reports · 2024Article
- Unravelling Surface Modification Strategies for Preventing Medical Device-Induced Thrombosis.Advanced healthcare materials · 2024Review
- Biomedical applications of engineered heparin-based materials.Bioactive materials · 2024Review
- Modified Diatomaceous Earth in Heparin Recovery from Porcine Intestinal Mucosa.Molecules (Basel, Switzerland) · 2023Article
- Quantitative Risk Evaluation of Adventitious Agents in Heparin.TH open : companion journal to thrombosis and haemostasis · 2023Review
- Approaches to Assure Similarity between Pharmaceutical Heparins from Two Different Manufacturers.Pharmaceutics · 2023Article
- Polyhydroxyalkanoate production from animal by-products: Development of a pneumatic feeding system for solid fat/protein-emulsions.Microbial biotechnology · 2023Article
- Efficient and Economic Heparin Recovery from Porcine Intestinal Mucosa Using Quaternary Ammonium-Functionalized Silica Gel.Bioengineering (Basel, Switzerland) · 2022Article
- Anticoagulant Activity of Heparins from Different Animal Sources are Driven by a Synergistic Combination of Physical-chemical Factors.TH open : companion journal to thrombosis and haemostasis · 2022Article
- Pharmacokinetic, Hemostatic, and Anticancer Properties of a Low-Anticoagulant Bovine Heparin.TH open : companion journal to thrombosis and haemostasis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purification of heparin from offal is an old industrial process for which commercial recipes date back to 1922. Although chemical, chemoenzymatic, and biotechnological alternatives for this production method have been published in the academic literature, animal-tissue is still the sole source for commercial heparin production in industry. Heparin purification methods are closely guarded industrial secrets which are not available to the general (scientific) public. However by reviewing the academic and patent literature, we aim to provide a comprehensive overview of the general methods used in industry for the extraction of heparin from animal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.